Israel Englander Stoke Therapeutics, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 20,396 shares of STOK stock, worth $275,957. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,396

Previous 19,620 3.96%

Holding current value

$275,957

Previous $130,000 77.69%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$5.9 - $11.84 $4,578 - $9,187	776 Added 3.96%	20,396 $231,000
Q1 2025 May 15, 2025	SELL	$6.65 - $12.74 $380,439 - $728,842	-57,209 Reduced 74.46%	19,620 $130,000
Q4 2024 Feb 14, 2025	BUY	$10.8 - $13.92 $669,535 - $862,956	61,994 Added 417.89%	76,829 $847,000
Q3 2024 Nov 14, 2024	SELL	$12.24 - $15.92 $3.36 Million - $4.37 Million	-274,232 Reduced 94.87%	14,835 $182,000
Q2 2024 Aug 14, 2024	BUY	$11.03 - $17.52 $2.68 Million - $4.26 Million	243,083 Added 528.63%	289,067 $3.91 Million
Q1 2024 May 15, 2024	BUY	$4.12 - $14.17 $90,928 - $312,731	22,070 Added 92.29%	45,984 $620,000
Q4 2023 Feb 14, 2024	SELL	$3.37 - $5.4 $1.45 Million - $2.33 Million	-431,201 Reduced 94.75%	23,914 $125,000
Q2 2023 Aug 14, 2023	BUY	$7.93 - $13.82 $2.28 Million - $3.97 Million	287,586 Added 171.66%	455,115 $4.84 Million
Q1 2023 May 15, 2023	SELL	$7.65 - $10.38 $1.93 Million - $2.61 Million	-251,650 Reduced 60.03%	167,529 $1.4 Million
Q4 2022 Feb 14, 2023	SELL	$7.07 - $15.69 $1.67 Million - $3.71 Million	-236,770 Reduced 36.1%	419,179 $3.87 Million
Q3 2022 Nov 14, 2022	SELL	$12.56 - $22.53 $3.69 Million - $6.62 Million	-293,709 Reduced 30.93%	655,949 $8.42 Million
Q2 2022 Aug 15, 2022	BUY	$10.36 - $23.93 $5.4 Million - $12.5 Million	521,661 Added 121.88%	949,658 $12.5 Million
Q1 2022 May 16, 2022	BUY	$17.19 - $26.1 $4.79 Million - $7.27 Million	278,372 Added 186.05%	427,997 $9.01 Million
Q4 2021 Feb 14, 2022	BUY	$18.11 - $30.72 $1.72 Million - $2.91 Million	94,800 Added 172.91%	149,625 $3.59 Million
Q3 2021 Nov 15, 2021	BUY	$23.65 - $34.44 $1.3 Million - $1.89 Million	54,825 New	54,825 $1.4 Million
Q2 2021 Aug 16, 2021	SELL	$30.53 - $41.09 $2.43 Million - $3.27 Million	-79,477 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$36.08 - $69.81 $2.87 Million - $5.55 Million	79,477 New	79,477 $3.09 Million
Q3 2020 Nov 16, 2020	SELL	$22.23 - $37.48 $5.65 Million - $9.53 Million	-254,229 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$20.26 - $29.73 $2.85 Million - $4.18 Million	140,736 Added 124.0%	254,229 $6.06 Million
Q1 2020 May 14, 2020	SELL	$16.8 - $34.15 $3.51 Million - $7.13 Million	-208,888 Reduced 64.8%	113,493 $2.6 Million
Q4 2019 Feb 14, 2020	SELL	$20.01 - $30.79 $7.51 Million - $11.6 Million	-375,430 Reduced 53.8%	322,381 $9.13 Million
Q3 2019 Nov 14, 2019	BUY	$20.53 - $37.72 $2.98 Million - $5.47 Million	145,081 Added 26.25%	697,811 $15 Million
Q2 2019 Aug 15, 2019	SELL	$25.53 - $29.17 $3.95 Million - $4.51 Million	-154,737 Reduced 21.87%	552,730 $16.1 Million
Q2 2019 Aug 14, 2019	BUY	$25.53 - $29.17 $18.1 Million - $20.6 Million	707,467 New	707,467 $34.2 Million

Others Institutions Holding STOK

# of Institutions

139

Shares Held

57.6M

Call Options Held

2.7K

Put Options Held

57.4K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $533M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account